Genmab A/S (NASDAQ:GMAB) Stock Price Expected to Rise, HC Wainwright Analyst Says

Genmab A/S (NASDAQ:GMAB) had its target price upped by equities research analysts at HC Wainwright from $38.00 to $40.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 44.72% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Wolfe Research assumed coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target on the stock. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. Truist Financial assumed coverage on Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.21.

Genmab A/S Trading Up 0.6%

GMAB opened at $27.64 on Thursday. Genmab A/S has a 12-month low of $20.23 and a 12-month high of $35.43. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The stock has a market capitalization of $17.23 billion, a PE ratio of 20.94, a P/E/G ratio of 1.77 and a beta of 0.84. The firm’s fifty day moving average price is $26.15 and its 200 day moving average price is $28.69.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC boosted its position in shares of Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after buying an additional 616 shares during the period. Osaic Holdings Inc. boosted its position in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the period. V Square Quantitative Management LLC bought a new position in shares of Genmab A/S in the first quarter worth $34,000. NewEdge Advisors LLC grew its stake in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its holdings in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.